| Utility
of proteomics in emerging and re-emerging infectious
diseases caused by RNA viruses |
10.1021/acs.jproteome.0c00380 |
(74) |
| Proteomics and informatics for understanding phases and identifying
biomarkers in COVID-19 disease |
10.1021/acs.jproteome.0c00326 |
(75) |
| Perspective on proteomics for virus detection in clinical samples |
10.1021/acs.jproteome.0c00674 |
(76) |
| Mass spectrometry techniques in
emerging pathogens studies:
COVID-19 perspectives |
10.1021/jasms.0c00238 |
(77) |
| The acute respiratory distress syndrome biomarker pipeline:
crippling gaps between discovery and clinical utility |
10.1016/j.trsl.2020.06.010 |
(78) |
| The role of biomarkers in diagnosis of COVID-19—A systematic
review |
10.1016/j.lfs.2020.117788 |
(79) |
| Predictors of COVID-19 severity: A literature review |
10.1002/rmv.2146 |
(80) |
| Hematologic, biochemical, and immune biomarker abnormalities
associated with severe illness and mortality in coronavirus disease
2019 (COVID-19): A meta-analysis |
10.1515/cclm-2020-0369 |
(81) |
| Biochemical biomarkers alterations in Coronavirus Disease 2019
(COVID-19) |
10.1515/dx-2020-0057 |
(82) |
| Biomarkers of COVID-19 and technologies to combat SARS-CoV-2 |
10.1016/j.abst.2020.08.001 |
(83) |
| A comprehensive overview of proteomics
approach for COVID 19:
new perspectives in target therapy strategies |
10.1007/s42485-020-00052-9 |
(12) |
| Proteomics in the COVID-19 battlefield: First semester check-up |
10.1002/pmic.202000198 |
(84) |
| A real-time dashboard of clinical trials for COVID-19 |
10.1016/S2589-7500(20)30086-8 |
(85) |
| Review of trials currently testing treatment and
prevention
of COVID-19 |
10.1016/j.cmi.2020.05.019 |
(86) |
